STOCK TITAN

Nyxoah SA - NYXH STOCK NEWS

Welcome to our dedicated news page for Nyxoah SA (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on Nyxoah SA.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nyxoah SA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nyxoah SA's position in the market.

Rhea-AI Summary
Nyxoah partners with AAO-HNSF to enhance patient access strategy, becoming the first medical device company at the ENTerprise Circle level. The collaboration aims to improve patient access to OSA treatments and navigate authorization requirements, FDA interactions, and clinical guidelines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.88%
Tags
partnership
-
Rhea-AI Summary
Nyxoah announces successful results from the DREAM U.S. pivotal study, showing a significant reduction in sleep apnea symptoms with high responder rates and promising safety profile. The study achieved a 70.8% median reduction in the Apnea-Hypopnea Index (AHI) and a 71.3% responder rate in the Oxygen Desaturation Index (ODI) on an intent to treat basis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.92%
Tags
clinical trial
-
Rhea-AI Summary
Nyxoah reported strong financial results for the fourth quarter and full year 2023, achieving record quarterly sales of €1.8 million. The company filed the third out of four modules in the U.S. modular PMA submission and ended the year with a total cash position of €57.7 million. Nyxoah plans to report DREAM U.S. pivotal study efficacy and safety data by early April and accelerate investments in the U.S. commercial organization for a late 2024 launch.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
earnings
Rhea-AI Summary
Nyxoah to participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference to showcase innovative solutions for Obstructive Sleep Apnea treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.07%
Tags
conferences
-
Rhea-AI Summary
Nyxoah SA (NYXH) will release its financial results for the fourth quarter and financial year 2023 on March 5, 2024. The Company, focused on treating Obstructive Sleep Apnea, will host a conference call to discuss the results. Investors can access the webcast through the Nyxoah website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
earnings
-
Rhea-AI Summary
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announced its strategic priorities for 2024, including completing patient follow-up in the DREAM U.S. pivotal study, filing the final module in the modular PMA submission, accelerating investments in the U.S. commercial organization, and increasing hypoglossal nerve stimulation market penetration and Genio market share in Europe. The company also emphasized its mission to improve the lives of OSA patients and highlighted the upcoming reporting of DREAM results as a significant milestone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.47%
Tags
none
Rhea-AI Summary
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces preliminary unaudited results for the fourth quarter and full year 2023, with anticipated revenue of approximately €1.8 million for Q4, a 40% increase over Q4 2022, and €4.3 million for the full year 2023, a 41% increase over 2022. The company also ended the year with 48 active German accounts. CEO Olivier Taelman expressed excitement for the strong sales growth, attributing it to the demand for Genio and streamlined patient referral pathways. The company anticipates an exciting 2024 with the upcoming DREAM US pivotal trial data, FDA approval filing, US market entry preparations, and contributions from the ResMed commercial partnership in Germany.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
earnings
-
Rhea-AI Summary
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announced positive results in treating complete concentric collapse (CCC) patients with the Genio® hypoglossal nerve stimulation system. Data presented at the DGSM Conference in Berlin by Dr. Christian Plettenberg on December 8, 2023, showed an average AHI decrease of 73%. The results demonstrated significant improvements in AHI and ESS, with no implant-related adverse events reported. The company's CEO, Olivier Taelman, expressed excitement about the potential FDA approval and the opportunity to bring Genio to CCC patients in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
none
-
Rhea-AI Summary
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) received a transparency notification from Deerfield Partners, L.P. indicating that they crossed the 3% threshold on November 30, 2023, holding 856,085 shares, representing 2.99% of the total number of voting rights on November 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announced the appointment of Francis Kim as Chief Regulatory and Quality Officer. With over 25 years of experience in the healthcare industry, Francis will lead Nyxoah’s Global Regulatory and Quality departments. His previous roles at Medtronic, Philips, and other companies make him a valuable addition to Nyxoah during a crucial period, with the DREAM U.S. pivotal study data expected in early 2024 and FDA approval anticipated by the end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
management
Nyxoah SA

Nasdaq:NYXH

NYXH Rankings

NYXH Stock Data

395.94M
10.99M
45.19%
23.83%
1.01%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Belgium
Mont Saint Guibert

About NYXH

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA).